Biostax Corp.
BTAX · OTC
9/30/2024 | 6/30/2024 | 3/31/2024 | |
|---|---|---|---|
| Valuation | |||
| PEG Ratio | 0.30 | -0.02 | 0.00 |
| FCF Yield | 0.00% | 0.00% | -0.69% |
| EV / EBITDA | 330.14 | -15.23 | -21.67 |
| Quality | |||
| ROIC | 2.70% | 7.26% | 7.34% |
| Gross Margin | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.09 | – | – |
| Growth | |||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 0.00% | 0.00% | 0.00% |
| Safety | |||
| Net Debt / EBITDA | 71.67 | -3.33 | -4.42 |
| Interest Coverage | -2.14 | -3.92 | -3.70 |
| Efficiency | |||
| Inventory Turnover | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 |